Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

Cited by (759)

Items 101–200 of 759

1. Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs
   Massimo Gadina, Catrina Johnson, Daniella M. Schwartz, Michael Markus Bonelli, Sarfaraz Hasni, Yuka Kanno, Paul S. Changelian, Arian D. J. Laurence, John J. O’Shea · 2018 · Journal of Leukocyte Biology
2. Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
   A. Kivitz, E. Olech, M. Borofsky, B. Zazueta, F. Navarro-Sarabia, S. Radominski, J. Merrill, L. Rowell, C. Nasmyth‐Miller, M. Bao et al. · 2014 · Arthritis care & research
3. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study
   M. Genovese, R. Fleischmann, D. Furst, Namieta M. Janssen, J. Carter, B. Dasgupta, J. Bryson, B. Duncan, Wei Zhu, C. Pitzalis et al. · 2014 · Annals of the Rheumatic Diseases
4. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)
   Marta Pérez-De-Lis, Soledad Retamozo, Alejandra Flores-Chávez, Belchin Kostov, R. Pérez-Álvarez, Pilar Brito‐Zerón, Manuel Ramos‐Casals · 2017 · Expert Opinion on Drug Safety
5. Dendritic cells as targets for therapy in rheumatoid arthritis
   Shaukat Ali Khan, Jeffrey D. Greenberg, Nina Bhardwaj · 2009 · Nature Reviews Rheumatology
6. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review
   M. Stevenson, R. Archer, J. Tosh, E. Simpson, E. Everson-Hock, John W. Stevens, Mónica Hernández-Alava, S. Paisley, Kath Dickinson, D. Scott et al. · 2016 · Health Technology Assessment
7. Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment
   Aprajita Jagpal, Iris Navarro-Millán · 2018 · BMC Rheumatology
8. Regulatory T cells as therapeutic targets in rheumatoid arthritis
   Jonathan H. Esensten, D. Wofsy, J. Bluestone · 2009 · Nature Reviews Rheumatology
9. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist.
   C. Charles-Schoeman, M. González-Gay, I. Kaplan, M. Boy, J. Geier, Zhen Luo, Andrea L. Zuckerman, R. Riese · 2016 · Seminars in Arthritis & Rheumatism
10. The role of the Th17 cytokines IL-17 and IL-22 in Rheumatoid Arthritis pathogenesis and developments in cytokine immunotherapy
    Debbie M. Roeleveld, Marije I. Koenders · 2014 · Cytokine
11. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study
    N. Nishimoto, K. Amano, Y. Hirabayashi, T. Horiuchi, T. Ishii, M. Iwahashi, M. Iwamoto, H. Kohsaka, M. Kondo, T. Matsubara et al. · 2013 · Modern Rheumatology
12. Risk of infections in rheumatoid arthritis patients treated with tocilizumab.
    Veronika R. Lang, M. Englbrecht, J. Rech, H. Nüßlein, K. Manger, F. Schuch, H. Tony, M. Fleck, B. Manger, G. Schett et al. · 2012 · Rheumatology
13. A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases
    A. Rubbert-Roth, D. Furst, J. Nebesky, Angela Jin, E. Berber · 2018 · Rheumatology and Therapy
14. Interleukin-6 aborts lymphopoiesis and elevates production of myeloid cells in systemic lupus erythematosus-prone B6.Sle1.Yaa animals.
    Kenichiro Maeda, A. Malykhin, Brittany N. Teague-Weber, Xiao-Hong Sun, A. D. Farris, K. Coggeshall · 2009 · Blood
15. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection
    M. Biggioggero, C. Crotti, A. Becciolini, E. Favalli · 2018 · Drug Design, Development and Therapy
16. Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective
    F. De Keyser · 2011 · Current Rheumatology Reviews
17. Clinical value of blocking IL-6 receptor
    Toru Mima, Norihiro Nishimoto · 2009 · Current Opinion in Rheumatology
18. Interleukin-6 as a Therapeutic Target in Candidate Inflammatory Diseases
    Naoki Nishimoto · 2010 · Clinical Pharmacology & Therapeutics
19. Design of the Tocilizumab in Giant Cell Arteritis Trial
    Sebastian H. Unizony, Bhaskar Dasgupta, Elena Fisheleva, Lucy Rowell, Georg Andreas Schett, Robert Spiera, Jochen Zwerina, Olivier Harari, John H. Stone · 2013 · International Journal of Rheumatology
20. An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy
    Vijay U. Rao, A. Pavlov, M. Klearman, D. Musselman, Jon T. Giles, J. Bathon, N. Sattar, J. S. Lee · 2015 · Arthritis & Rheumatology
21. Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers.
    T. Dörner, N. Kinnman, P. Tak · 2010 · Pharmacology and Therapeutics
22. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)
    G. Burmester, A. Rubbert-Roth, A. Cantagrel, S. Hall, P. Leszczyński, D. Feldman, M. J. Rangaraj, G. Roane, C. Ludivico, M. Bao et al. · 2014 · Annals of the Rheumatic Diseases
23. Population Pharmacokinetic Analysis of Tocilizumab in Patients With Rheumatoid Arthritis
    N. Frey, S. Grange, T. Woodworth · 2010 · Journal of clinical pharmacology
24. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement
    M. Schoels, D. M. van der Heijde, F. Breedveld, G. Burmester, M. Dougados, P. Emery, G. Ferraccioli, C. Gabay, A. Gibofsky, J. Gómez-Reino et al. · 2012 · Annals of the Rheumatic Diseases
25. The role of interleukin-6 in glucose homeostasis and lipid metabolism
    Lehrskov, Louise Lang, Christensen, Regitse Højgaard · 2019 · Seminars in Immunopathology
26. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis
    Jie Zhang, F. Xie, H. Yun, Lang Chen, P. Muntner, E. Levitan, M. Safford, Shia T. Kent, M. Osterman, James D. Lewis et al. · 2016 · Annals of the Rheumatic Diseases
27. Tocilizumab Inhibits Structural Joint Damage and Improves Physical Function in Patients with Rheumatoid Arthritis and Inadequate Responses to Methotrexate: LITHE Study 2-year Results
    R. Fleischmann, A. Halland, M. Brzosko, R. Burgos-Vargas, C. Mela, E. Vernon, J. Kremer · 2013 · Journal of Rheumatology
28. Matrix Metalloproteinase Gene Activation Resulting from Disordred Epigenetic Mechanisms in Rheumatoid Arthritis
    Yasuto Araki, Toshihide Mimura · 2017 · International Journal of Molecular Sciences
29. IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis
    Lauren M. F. Merlo, Elizabeth Pigott, J. DuHadaway, Samantha Grabler, R. Metz, G. Prendergast, L. Mandik-Nayak · 2014 · Journal of Immunology
30. Cyr61 Induces IL-6 Production by Fibroblast-like Synoviocytes Promoting Th17 Differentiation in Rheumatoid Arthritis
    Jin-Piao Lin, Zhou Zhou, Rong-Fen Huo, Lian-Bo Xiao, Gui-Lin Ouyang, Li Wang, Yue Sun, Bai-Hua Shen, Dang-Sheng Li, Ning-Li Li · 2012 · Journal of Immunology
31. Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis
    K. Hayward, C. Wallace · 2009 · Arthritis Research & Therapy
32. Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis
    Fawziah Marra, Elaine Ah‐Gi Lo, Viktor Kalashnikov, Kathryn Richardson · 2016 · Open Forum Infectious Diseases
33. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study
    V. Strand, G. Burmester, S. Ogale, J. Devenport, A. John, P. Emery · 2012 · Rheumatology
34. In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment.
    P. Roll, K. Muhammad, M. Schumann, S. Kleinert, H. Einsele, T. Dörner, H. Tony · 2011 · Arthritis & Rheumatism
35. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs.
    G. Bergman, M. Hochberg, M. Boers, N. Wintfeld, A. Kielhorn, J. Jansen · 2010 · Seminars in Arthritis & Rheumatism
36. Tocilizumab: A Review of Its Safety and Efficacy in Rheumatoid Arthritis
    G. Jones, C. Ding · 2010 · Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
37. The vasculature in rheumatoid arthritis: cause or consequence?
    E. Paleolog · 2009 · International journal of experimental pathology (Print)
38. Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice.
    Y. Pers, C. Fortunet, É. Constant, J. Lambert, M. Godfrin-Valnet, Audrey de Jong, G. Mercier, Béatrice Pallot-Prades, D. Wendling, P. Gaudin et al. · 2014 · Rheumatology
39. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis
    R. Rossotti, G. Travi, N. Ughi, M. Corradin, C. Baiguera, R. Fumagalli, M. Bottiroli, M. Mondino, M. Merli, A. Bellone et al. · 2020 · Journal of Infection
40. Tocilizumab in the treatment of rheumatoid arthritis and beyond
    A. Shetty, Rebekah L Hanson, P. Korsten, Munir Shawagfeh, S. Arami, S. Volkov, Olga M. Vila, W. Swedler, Abdel Naser Shunaigat, S. Smadi et al. · 2014 · Drug Design, Development and Therapy
41. Effects of inflammatory cytokine IL-27 on the activation of fibroblast-like synoviocytes in rheumatoid arthritis
    Chun Kwok Wong, Da P Chen, Lai‐Shan Tam, Edmund K. Li, Yi Bing Yin, Christopher WK Lam · 2010 · Arthritis Research & Therapy
42. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice
    V. Bykerk, A. Östör, J. Álvaro-Gracia, K. Pavelka, J. Ivorra, W. Graninger, W. Bensen, M. Nurmohamed, A. Krause, C. Bernasconi et al. · 2012 · Annals of the Rheumatic Diseases
43. Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis.
    Isaacs, John D, Harari, Olivier, Kobold, Uwe, Lee, Janet S, Bernasconi, Corrado · 2013 · Arthritis Research & Therapy
44. Biologic interventions for fatigue in rheumatoid arthritis.
    C. Almeida, E. Choy, S. Hewlett, J. Kirwan, F. Cramp, T. Chalder, J. Pollock, R. Christensen · 2016 · Cochrane Database of Systematic Reviews
45. What is the future of targeted therapy in rheumatology: biologics or small molecules?
    Attila Mócsai, László Kovács, Péter Attila Gergely · 2014 · BMC Medicine
46. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis.
    A. Strang, R. Bisoendial, R. Kootte, D. Schulte, G. Dallinga-Thie, J. Levels, M. Kok, K. Vos, S. Tas, U. Tietge et al. · 2013 · Atherosclerosis
47. Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan
    Kazuhiko Yamamoto, H. Goto, K. Hirao, A. Nakajima, H. Origasa, Kunihiko Tanaka, Minako Tomobe, K. Totsuka · 2015 · Journal of Rheumatology
48. [Update of the Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis].
    Jesús Tornero Molina, R. Sanmartí-Sala, Vicente Rodríguez-Valverde, Emilio Martín-Mola, J. L. Marenco de la Fuente, I. González-Álvaro, Santiago Muñoz Fernández, J. Gómez-ReinoCarnota, Luis Carreño Pérez, E. Batlle-Gualda et al. · 2010 · Reumatología Clínica
49. Pathogenic stromal cells as therapeutic targets in joint inflammation
    Stephanie Georgina Dakin, Mark Christopher Coles, Jonathan P. Sherlock, Fiona M. Powrie, Andrew Jonathan Carr, Christopher Dominic Buckley · 2018 · Nature Reviews Rheumatology
50. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis
    G. Burmester, E. Choy, A. Kivitz, A. Ogata, M. Bao, Akira Nomura, Stuart Lacey, J. Pei, W. Reiss, A. Pethoe-Schramm et al. · 2016 · Annals of the Rheumatic Diseases
51. Prediction of Therapeutic Responses to Tocilizumab in Patients With Rheumatoid Arthritis: Biomarkers Identified by Analysis of Gene Expression in Peripheral Blood Mononuclear Cells Using Genome‐Wide DNA Microarray
    Y. Sanayama, K. Ikeda, Yukari Saito, S. Kagami, M. Yamagata, S. Furuta, D. Kashiwakuma, I. Iwamoto, T. Umibe, Y. Nawata et al. · 2014 · Arthritis & Rheumatology
52. Tocilizumab for the treatment of rheumatoid arthritis
    Toshio Tanaka, A. Ogata, M. Narazaki · 2010 · Expert Review of Clinical Immunology
53. Glucocorticoid-induced leucine zipper is an endogenous antiinflammatory mediator in arthritis.
    É. Beaulieu, Devi Ngo, L. Santos, Yuan H. Yang, Malcolm D. Smith, C. Jorgensen, V. Escriou, D. Scherman, G. Courties, F. Apparailly et al. · 2010 · Arthritis & Rheumatism
54. Interleukin-6 in atherosclerosis: atherogenic or atheroprotective?
    A. Reiss, Nicolle M. Siegart, J. De Leon · 2017 · Clinical Lipidology
55. The role of IL-6 and IL-6 blockade in COVID-19
    Nicola Potere, Alberto Batticciotto, Alessandra Vecchié, Ettore Porreca, Antonella Cappelli, Antonio Abbate, Francesco Dentali, Aldo Bonaventura · 2021 · Expert Review of Clinical Immunology
56. Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis
    P. Emery, J. Rondón, J. Parrino, Yong Lin, C. Peña-Rossi, H. V. van Hoogstraten, N. Graham, Nancy X. Liu, A. Paccaly, Richard Wu et al. · 2018 · Rheumatology
57. The Correlation between Increased Serum Concentrations of Interleukin-6 Family Cytokines and Disease Activity in Rheumatoid Arthritis Patients
    Soo-jin Chung, Yong-Jin Kwon, Min-Chan Park, Yong-Beom Park, Soo-Kon Lee · 2010 · Yonsei medical journal
58. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study)
    H. Yamanaka, Yoshiya Tanaka, E. Inoue, D. Hoshi, S. Momohara, K. Hanami, N. Yunoue, Kazuyoshi Saito, K. Amano, H. Kameda et al. · 2010 · Modern Rheumatology
59. Targeting IL-6 in the treatment of inflammatory and autoimmune diseases
    C. Ding, F. Cicuttini, Jun Li, G. Jones · 2009 · Expert Opinion on Investigational Drugs
60. Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in Japan
    Ken Nakajima, Omi Watanabe, Mayumi Mochizuki, Ayako Nakasone, Nobuhiko Ishizuka, Atsuko Murashima · 2016 · Modern Rheumatology
61. Elevated serum interleukin-6 is predictive of coronary artery disease in intermediate risk overweight patients referred for coronary angiography
    M. Wainstein, Márcio Mossmann, G. Araujo, S. Gonçalves, G. Gravina, M. Sangalli, Francine Veadrigo, R. Matte, Rejane Reich, Fernanda G. Costa et al. · 2017 · Diabetology & Metabolic Syndrome
62. Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums.
    Geraldine M Navarro, Sara Taroumian, N. Barroso, L. Duan, D. Furst · 2014 · Seminars in Arthritis & Rheumatism
63. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size
    Hong Zhao, Qi Zhu, Chi Zhang, Jiawen Li, Ming Wei, Yuhong Qin, Guilin Chen, Ke Wang, Junhua Yu, Zhao Wu et al. · 2020 · Biomedicine & Pharmacotherapy
64. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study
    Daniel Aletaha, Clifton O. Bingham, Yoshiya Tanaka, Prasheen Agarwal, Regina Kurrasch, Paul Peter Tak, Sharon Popik · 2017 · The Lancet
65. Increased Tim-3 expression on peripheral lymphocytes from patients with rheumatoid arthritis negatively correlates with disease activity.
    Ying Liu, Q. Shu, Li-Fen Gao, Nan Hou, Di Zhao, Xiao Liu, Xiaoning Zhang, Li-Yun Xu, Xue-Tian Yue, F. Zhu et al. · 2010 · Clinical Immunology
66. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis
    R. Koike, M. Harigai, T. Atsumi, K. Amano, S. Kawai, Kazuyoshi Saito, T. Saito, M. Yamamura, T. Matsubara, N. Miyasaka · 2009 · Modern Rheumatology
67. Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials
    R. Moots, A. Sebba, W. Rigby, A. Ostor, Benjamin Porter-Brown, F. Donaldson, S. Dimonaco, A. Rubbert-Roth, R. van Vollenhoven, M. Genovese · 2016 · Rheumatology
68. Tuberculosis Risk in Patients Treated with Non-Anti-Tumor Necrosis Factor-α (TNF-α) Targeted Biologics and Recently Licensed TNF-α Inhibitors: Data from Clinical Trials and National Registries
    F. Cantini, L. Niccoli, D. Goletti · 2014 · Journal of Rheumatology Supplement
69. Targeting IL-17 and Th17 Cells in Rheumatoid Arthritis
    Sujata Sarkar, David A. Fox · 2010 · Rheumatic Disease Clinics of North America
70. The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis
    C. Edwards, E. Williams · 2010 · Osteoporosis International
71. Short‐course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation
    Le-Feng Chen, Y. Mo, J. Jing, Jian-Da Ma, Dong-hui Zheng, L. Dai · 2017 · International Journal of Rheumatic Diseases
72. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.
    Jasvinder A. Singh, Alomgir Hossain, Elizabeth Tanjong-Ghogomu, Ahmed Kotb, R. Christensen, A. Mudano, Lara J. Maxwell, Nipam P. Shah, P. Tugwell, G. Wells · 2016 · Cochrane Database of Systematic Reviews
73. Optimization of current and future therapy for autoimmune diseases
    Lawrence Steinman, Joan T. Merrill, Iain B. McInnes, Mark Peakman · 2012 · Nature Medicine
74. Systemic rheumatic diseases: From biological agents to small molecules.
    P. Sarzi-Puttini, A. Ceribelli, D. Marotto, A. Batticciotto, F. Atzeni · 2019 · Autoimmunity Reviews
75. Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis.
    M. Lahiri, W. Dixon · 2015 · Baillière's Best Practice & Research : Clinical Rheumatology
76. Forget personalised medicine and focus on abating disease activity
    J. Smolen, D. Aletaha · 2012 · Annals of the Rheumatic Diseases
77. Rheumatoid anemia
    Masson, Charles · 2011 · Joint Bone Spine
78. RETRACTED: Rheumatoid arthritis (RA) and cardiovascular disease
    Arnon Blum, Mohammad Adawi · 2019 · Autoimmunity Reviews · Retracted
79. A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab
    S. Kawashiri, A. Kawakami, N. Sakamoto, Y. Ishimatsu, K. Eguchi · 2012 · Rheumatology International
80. ▼Tocilizumab for rheumatoid arthritis
    BMJ Publishing Group Ltd · 2009 · Drug and Therapeutics Bulletin
81. Immunomodulation in the critically ill
    N. Webster, H. Galley · 2009 · British Journal of Anaesthesia
82. Extra-respiratory manifestations of COVID-19
    Chih‐Cheng Lai, Wen‐Chien Ko, Ping‐Ing Lee, Shio‐Shin Jean, Po‐Ren Hsueh · 2020 · International Journal of Antimicrobial Agents
83. A new era for giant cell arteritis
    H. Lyons, V. Quick, A. Sinclair, Santhosh Nagaraju, S. Mollan · 2019 · Eye
84. Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy
    Aarat M. Patel, L. Moreland · 2010 · Drug Design, Development and Therapy
85. Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long‐Term Clinical Trial Safety Data in Rheumatoid Arthritis
    Mark C. Genovese, Joel M. Kremer, Ronald van Vollenhoven, Rieke Alten, Juan Jose Scali, Ariella Kelman, Sophie Dimonaco, Laura Brockwell · 2017 · Arthritis & Rheumatology
86. Validation of the Methotrexate‐First Strategy in Patients With Early, Poor‐Prognosis Rheumatoid Arthritis: Results From a Two‐Year Randomized, Double‐Blind Trial
    James R. O’Dell, Jeffrey R. Curtis, Ted R. Mikuls, Stacey S. Cofield, S. Louis Bridges, Veena K. Ranganath, Larry W. Moreland, for the TEAR Trial Investigators · 2013 · Arthritis & Rheumatism
87. Targeting Interleukin-6 in Rheumatoid Arthritis
    M. M. Md Yusof, P. Emery · 2013 · Drugs
88. The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis
    Katina Schinnerling, Juan Carlos Aguillón, Diego Catalán, Lilian Soto · 2017 · Clinical & Experimental Immunology
89. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial
    G. Burmester, W. Rigby, R. van Vollenhoven, J. Kay, A. Rubbert-Roth, R. Blanco, A. Kadva, S. Dimonaco · 2017 · Annals of the Rheumatic Diseases
90. Safety and Efficacy of Tocilizumab for the Treatment of Rheumatoid Arthritis
    A. Ogata, T. Hirano, Yoshihiro Hishitani, Toshio Tanaka · 2012 · Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
91. The progress and prospect of regulatory T cells in autoimmune diseases
    Ximei Zhang, Nancy J. Olsen, Song Guo Zheng · 2020 · Journal of Autoimmunity
92. Interleukin 6 in hyposmia.
    R. Henkin, Loren Schmidt, I. Velicu · 2013 · JAMA Otolaryngology - Head and Neck Surgery
93. Effectiveness of Biologic Therapies for Rheumatoid Arthritis: An Indirect Comparisons Approach
    E. Devine, R. Alfonso-Cristancho, Sean D. Sullivan · 2011 · Pharmacotherapy
94. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs – a systematic review and network meta-analysis
    J. Jansen, F. Buckley, F. Dejonckheere, S. Ogale · 2014 · Health and Quality of Life Outcomes
95. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
    K. Stubenrauch, Uwe Wessels, H. Birnboeck, Francisco Ramirez, A. Jahreis, J. Schleypen · 2010 · Clinical Therapeutics
96. New therapies in the management of rheumatoid arthritis
    M. Buch, P. Emery · 2011 · Current Opinion in Rheumatology
97. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
    Jasvinder A. Singh, Alomgir Hossain, Elizabeth Tanjong-Ghogomu, A. Mudano, P. Tugwell, G. Wells · 2016 · Cochrane Database of Systematic Reviews
98. Interleukin-6/STAT3 pathway signaling drives an inflammatory phenotype in Group A ependymoma
    A. Griesinger, R. Josephson, A. Donson, J. M. Mulcahy Levy, V. Amani, D. Birks, L. Hoffman, Steffanie L Furtek, Phillip Reigan, M. Handler et al. · 2015 · Cancer immunology research
99. Atherogenic Index and High-Density Lipoprotein Cholesterol as Cardiovascular Risk Determinants in Rheumatoid Arthritis: The Impact of Therapy with Biologicals
    C. Popa, E. Arts, J. Fransen, P. van Riel · 2012 · Mediators of Inflammation
100. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
     Jasvinder A. Singh, Alomgir Hossain, A. Mudano, Elizabeth Tanjong-Ghogomu, M. Suarez-Almazor, R. Buchbinder, Lara J. Maxwell, P. Tugwell, G. Wells · 2017 · Cochrane Database of Systematic Reviews